William R.  Carapezzi, Jr. net worth and biography

William Carapezzi, Jr. Biography and Net Worth

EVP of Pfizer
Bill Carapezzi is Executive Vice President, Global Business Services and Transformation, responsible for global procurement, global financial shared services, human resources operations, real estate, and the financial project management office, as well as for elements of commercial operations.

Previously, Bill was Senior Vice President of Global Business Operations. In this role, Bill led global financial solutions, procurement, workplace solutions, tax, insurance and the financial portfolio management office. Bill joined Pfizer in March 2008 as the Senior Vice President of Global Tax.

Prior to joining Pfizer, Bill was with Lucent Technologies, Inc., for 18 years in a variety of roles including Executive Vice President & General Counsel and Vice President of Treasury & Tax. In addition, Bill spent six years in public accounting at Arthur Andersen & Co.

Bill holds a Bachelor of Science degree in Accounting from Fairfield University, a Juris Doctor (JD) from Western New England School of Law, and a LL.M in Taxation from New York University School of Law. He is also a Certified Public Accountant.

What is William R. Carapezzi, Jr.'s net worth?

The estimated net worth of William R. Carapezzi, Jr. is at least $984,929.72 as of May 12th, 2022. Mr. Carapezzi, Jr. owns 38,146 shares of Pfizer stock worth more than $984,930 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Carapezzi, Jr. may own. Learn More about William R. Carapezzi, Jr.'s net worth.

How do I contact William R. Carapezzi, Jr.?

The corporate mailing address for Mr. Carapezzi, Jr. and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on William R. Carapezzi, Jr.'s contact information.

Has William R. Carapezzi, Jr. been buying or selling shares of Pfizer?

William R. Carapezzi, Jr. has not been actively trading shares of Pfizer over the course of the past ninety days. Most recently, William R. Carapezzi, Jr. sold 32,908 shares of the business's stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a transaction totalling $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares of the company's stock, valued at $1,907,300. Learn More on William R. Carapezzi, Jr.'s trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, Pfizer insiders bought shares 2 times. They purchased a total of 4,000 shares worth more than $107,650.00. The most recent insider tranaction occured on October, 30th when Director Scott Gottlieb bought 1,000 shares worth more than $28,240.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 10/30/2024.

William R. Carapezzi, Jr. Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Sell32,908$50.00$1,645,400.0038,146View SEC Filing Icon  
See Full Table

William R. Carapezzi, Jr. Buying and Selling Activity at Pfizer

This chart shows William R Carapezzi Jr's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $25.72
Low: $25.71
High: $25.90

50 Day Range

MA: $27.83
Low: $24.80
High: $30.20

2 Week Range

Now: $25.72
Low: $24.48
High: $31.54

Volume

13,003,974 shs

Average Volume

38,342,375 shs

Market Capitalization

$145.75 billion

P/E Ratio

34.76

Dividend Yield

6.41%

Beta

0.65